Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
AFG3L2 pseudogene 1 (AFG3L2P1), also known as AFG3L1 in humans, is a non-functional pseudogene related to the functional AFG3L2 gene. In humans, AFG3L1 has lost its protein-coding potential and does not produce an active protein, nor does it participate in m-AAA protease complex formation. While the functional AFG3L2 gene encodes a mitochondrial AAA+ protease subunit essential for protein quality control and mitochondrial function, the AFG3L2P1 pseudogene itself does not contribute to these activities or any other biological functions in humans. Unlike the mouse ortholog, human AFG3L1 is nonfunctional, even though it may show low-level expression. AFG3L2P1 is not considered an active target, enzyme, or receptor, and there are no known drugs, clinical biomarkers, or therapeutic applications associated with it. Mutations in the functional AFG3L2 gene have been linked to neurodegenerative disorders like spinocerebellar ataxia, but the pseudogene has no such associations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on AFG3L2 pseudogene 1 (AFG3L2P1).